Search
for
Sort by
Research 241–270 of 671
- Physiologic skin changes in pregnancy
- Polycystic ovary syndrome — the skin as a mirror of endocrine disorders
- Endocrine Treatment of Transsexual Persons:An Endocrine Society Clinical Practice Guideline
- Is dehydroepiandrosterone a hormone?
- The Neurobiology of Sexual Function
- Alopecia areata
- Genetic, hormonal and metabolic aspects of PCOS: an update
- Roles for Msx and Dlx homeoproteins in vertebrate development
- Use of cyproterone acetate (CPA) in the treatment of acne, hirsutism and virilism
- Polycystic Ovary Syndrome, Insulin Resistance, and Obesity: Navigating the Pathophysiologic Labyrinth
- Dermatoses of pregnancy
- Medical uses of Carthamus tinctorius L. (Safflower): a comprehensive review from Traditional Medicine to Modern Medicine
- Vitamin D and the skin: Focus on a complex relationship: A review
- Tissue Engineering and Regenerative Medicine: Achievements, Future, and Sustainability in Asia
- Polycystic Ovary Syndrome
- Safety of testosterone treatment in postmenopausal women
- Physiological and biological skin changes in pregnancy
- Animal models for the study of fetal tissue repair
- Pathways to inflammation: acne pathophysiology
- Effect of estrogens on skin aging and the potential role of selective estrogen receptor modulators
- Finasteride Blocks the Reduction in Ictal Activity Produced by Exogenous Estrous Cyclicity
- The role of lymphocytes in the development and treatment of alopecia areata
- Sex Hormone-Binding Globulin (SHBG) as an Early Biomarker and Therapeutic Target in Polycystic Ovary Syndrome
- 46,XY DSD due to impaired androgen production
- Increased Androgen Binding Capacity in Sebaceous Glands in Scalp of Male-pattern Baldness
- The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells
- Expression and roles of steroidogenic acute regulatory (StAR) protein in ‘non-classical’, extra-adrenal and extra-gonadal cells and tissues
- 5α-Reduced glucocorticoids: a story of natural selection
- The safety of 52 weeks of oral DHEA therapy for postmenopausal women
- Alternative treatment of polycystic ovary syndrome: pre-clinical and clinical basis for using plant-based drugs